Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance

被引:22
作者
Inoue, Hiroshi [1 ]
Uchiyama, Shinichiro [2 ]
Atarashi, Hirotsugu [3 ]
Okumura, Ken [4 ]
Koretsune, Yukihiro [5 ]
Yasaka, Masahiro [6 ]
Yamashita, Takeshi [7 ]
Ohnishi, Makiko [8 ]
Yagi, Nobutaka [9 ]
Fukaya, Taku [10 ]
机构
[1] Saiseikai Toyama Hosp, 33-1 Kusunoki, Toyama 9318533, Japan
[2] Int Univ Hlth & Welfare, Clin Res Ctr Med, Tokyo, Japan
[3] Tama Nagayama Hosp, Nippon Med Sch, Dept Internal Med & Cardiol, Sendai, Miyagi, Japan
[4] Hirosaki Univ, Grad Sch Med, Dept Cardiol, Hirosaki, Aomori, Japan
[5] Natl Hosp Org Osaka Natl Hosp, Inst Clin Res, Osaka, Japan
[6] Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Dept Cerebrovasc Dis, Osaka, Japan
[7] Cardiovasc Inst, Dept Cardiovasc Med, Tokyo, Japan
[8] Nippon Boehringer Ingelheim Co Ltd, Pharmacovigilance Dept, Shinagawa, Japan
[9] Nippon Boehringer Ingelheim Co Ltd, Med Data Serv Dept, Shinagawa, Japan
[10] Nippon Boehringer Ingelheim Co Ltd, Clin Dev & Med Affairs, Shinagawa, Japan
关键词
Atrial fibrillation; Anticoagulants; Post-marketing surveillance; Dabigatran; Japan;
D O I
10.1016/j.joa.2015.11.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aim: A post-marketing surveillance (PMS) study is being conducted to investigate the safety and effectiveness of the long-term use of dabigatran etexilate (dabigatran) in Japanese patients with nonvalvular atrial fibrillation (NVAF). Results of an interim analysis of this prospective cohort study including patient characteristics and adverse drug reactions (ADRs) collected up to September 17, 2014 are reported here. Methods: Patients with NVAF who began to receive dabigatran for the first time from December 2011 to November 2013 were enrolled at 1042 study sites in Japan. Clinical parameters included patient characteristics, dabigatran dose strength, concomitant medications and outcome events. All outcome events were collected as serious and non-serious adverse events (AEs). ADRs were evaluated in this report. Pre-defined safety events of special interest for intensive survey were serious and non-serious outcome events such as myocardial infarction, as well as the total number of hemorrhage and gastrointestinal disorders. Results: A total of 6772 patients were registered. The safety analysis set included 6148 patients; mean age was 70.8 +/- 9.9 (SD) years: 2323 patients (37.8%) were aged 75 years or older. Males accounted for 66.8% of the patients. Mean CHADS(2) score was 1.8 +/- 1.3; the CHADS2 score was 0 in 13.6%, 1 in 31.3%, 2 in 25.9%, 3 in 14.9%, and 4 to 6 in 11.1% of the patients. Of the 6148 patients, 1701 patients (27.7%) were switchers from warfarin and 4407 patients (71.7%) were non-switchers (OAC naive patients). Treatment adherence was assessed for the first 3 months from the start of treatment for this analysis. Total 5656 patients (92.0%) reported taking dabigatran twice daily (bid) every day according to the label recommendation. During the follow up period [mean duration of follow up: 498 +/- 259 days (corresponding to 8386 patient-years)], predefined safety events of special interest for intensive survey (reported as serious ADRs) were: myocardial infarction, reported in 5 patients (0.06 per 100 patient-years); serious hemorrhage, reported in 46 patients (0.55 per 100 patient-years); and gastrointestinal disorders (non-hemorrhagic), reported in 11 patients (0.13 per 100 patient-years). Fifteen patients had ADRs with fatal outcome. Conclusions: The interim findings from this 6148 patient PMS study further corroborate the favorable safety profile of dabigatran as demonstrated previously in controlled clinical trials. (ClinicalTrials.gov number, NC101491178.) (C) 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V.
引用
收藏
页码:145 / 150
页数:6
相关论文
共 12 条
[1]   Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry [J].
Akao, Masaharu ;
Chun, Yeong-Hwa ;
Wada, Hiromichi ;
Esato, Masahiro ;
Hashimoto, Tetsuo ;
Abe, Mitsuru ;
Hasegawa, Koji ;
Tsuji, Hikari ;
Furuke, Keizo .
JOURNAL OF CARDIOLOGY, 2013, 61 (3-4) :260-266
[2]   Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation - A Report From the J-RHYTHM Registry [J].
Atarashi, Hirotsugu ;
Inoue, Hiroshi ;
Okumura, Ken ;
Yamashita, Takeshi ;
Kumagai, Naoko ;
Origasa, Hideki .
CIRCULATION JOURNAL, 2011, 75 (06) :1328-1333
[3]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[4]   Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation [J].
Gage, BF ;
Waterman, AD ;
Shannon, W ;
Boechler, M ;
Rich, MW ;
Radford, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22) :2864-2870
[5]   Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation [J].
Graham, David J. ;
Reichman, Marsha E. ;
Wernecke, Michael ;
Zhang, Rongmei ;
Southworth, Mary Ross ;
Levenson, Mark ;
Sheu, Ting-Chang ;
Mott, Katrina ;
Goulding, Margie R. ;
Houstoun, Monika ;
MaCurdy, Thomas E. ;
Worrall, Chris ;
Kelman, Jeffrey A. .
CIRCULATION, 2015, 131 (02) :157-164
[6]   Dabigatran Versus Warfarin Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation [J].
Hori, Masatsugu ;
Connolly, Stuart J. ;
Zhu, Jun ;
Liu, Li Sheng ;
Lau, Chu-Pak ;
Pais, Prem ;
Xavier, Denis ;
Kim, Sung Soon ;
Omar, Razali ;
Dans, Antonio L. ;
Tan, Ru San ;
Chen, Jyh-Hong ;
Tanomsup, Supachai ;
Watanabe, Mitsunori ;
Koyanagi, Masahide ;
Ezekowitz, Michael D. ;
Reilly, Paul A. ;
Wallentin, Lars ;
Yusuf, Salim .
STROKE, 2013, 44 (07) :1891-+
[7]   Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013) - Digest Version [J].
Inoue, Hiroshi ;
Atarashi, Hirotsugu ;
Kamakura, Shiro ;
Koretsune, Yukihiro ;
Kumagai, Koichiro ;
Mitamura, Hideo ;
Okumura, Ken ;
Sugi, Kaoru ;
Yamashita, Takeshi ;
Yasaka, Masahiro ;
Satomi, Kazuhiro ;
Kodama, Itsuo ;
Ogawa, Satoshi ;
Ohe, Tohru ;
Tsutsui, Hiroyuki .
CIRCULATION JOURNAL, 2014, 78 (08) :1997-2021
[8]   Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination [J].
Inoue, Hiroshi ;
Fujiki, Akira ;
Origasa, Hideki ;
Ogawa, Satoshi ;
Okumura, Ken ;
Kubota, Isao ;
Aizawa, Yoshifusa ;
Yamashita, Takeshi ;
Atarashi, Hirotsugu ;
Horie, Minoru ;
Ohe, Tohru ;
Doi, Yoshinori ;
Shimizu, Akihiko ;
Chishaki, Akiko ;
Saikawa, Tetsunori ;
Yano, Katsusuke ;
Kitabatake, Akira ;
Mitamura, Hideo ;
Kodama, Itsuo ;
Kamakura, Shiro .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 137 (02) :102-107
[9]   Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation [J].
Larsen, Torben Bjerregaard ;
Gorst-Rasmussen, Anders ;
Rasmussen, Lars Hvilsted ;
Skjoth, Flemming ;
Rosenzweig, Mary ;
Lip, Gregory Y. H. .
AMERICAN JOURNAL OF MEDICINE, 2014, 127 (07) :650-+
[10]   Myocardial Ischemic Events in 'Real World' Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin [J].
Larsen, Torben Bjerregaard ;
Rasmussen, Lars Hvilsted ;
Gorst-Rasmussen, Anders ;
Skjoth, Flemming ;
Rosenzweig, Mary ;
Lane, Deirdre A. ;
Lip, Gregory Y. H. .
AMERICAN JOURNAL OF MEDICINE, 2014, 127 (04) :329-+